On January 14, 2026, Robert W. Baird analyst Eric Coldwell raised his price target for McKesson, implying roughly a 16.2% upside from recent levels. This marks the second upward revision on MCK in the past quarter and follows stronger-than-expected earnings momentum in the distribution segment. Coldwell cited accelerating margin expansion in specialty pharmaceuticals and advanced data analytics services as key drivers for his optimism.

Recent SEC filings show GWN Securities Inc. established a new position of 3,570 shares in McKesson valued at approximately $2.8 million during Q3, while Solstein Capital LLC enlarged its holding by 171.4% in Q2, now accounting for 38 shares in its portfolio. Additional newcomers include the State of Wyoming, GFG Capital LLC and Delos Wealth Advisors LLC, each taking stakes valued between $29,000 and $35,000. These moves underscore growing confidence among hedge funds and pension plans in McKesson’s long-term supply-chain resilience.

As a leading healthcare services and IT provider, McKesson remains pivotal in moving pharmaceuticals and medical supplies to pharmacies, hospitals and clinics across the U.S. and globally. The company outpaces competitors such as Cardinal Health and AmerisourceBergen in specialty distribution and technology integration. McKesson’s market capitalization exceeds $100 billion, and trading volumes have stayed robust, reflecting investor interest in its efforts to expand clinical analytics offerings and optimize logistics networks.